Biosimilar products for bone disease treatment, namely, biosimilar preparations for the treatment of osteoporosis, bone cancer, osteomyelitis, osteogenesis imperfecta, treatment of bone loss associated with hormonal suppression in men with prostate cancer at high risk of fractures, treatment of bone loss in men with prostate cancer undergoing hormonal suppression, and treatment to prevent risk of vertebral fractures